15 December 2025

Physiomics plc

("Physiomics" or the "Company")

Physiomics Awarded Follow On Contract by UK Client

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a follow on contract with an existing UK based-client.

This new project builds on the contract award announced on 9 May 2025, under which Physiomics assisted its client in developing a population Pharmacokinetic (PK) model to inform the design of a Phase 2 clinical study for a small molecule therapeutic targeting rheumatoid arthritis. As the client prepares to initiate their clinical trial, this latest contract reflects a continued commitment to support the project throughout the execution of the Phase 2 study. Due to timelines associated with patient recruitment and data generation, this project is not anticipated to commence until 2027. The extended period between contract signature and project commencement is attributable to the client's desire to secure key service providers before initiating the trial. Upon initiation, the project is expected to run for approximately six months and due to flexibility in the scope of work has a value between £116K and £169K.

Dr Peter Sargent, CEO of Physiomics, commented:

"We are thrilled to have been awarded this new contract and to have the opportunity to continue supporting our client through their Phase 2 trial. This offers Physiomics an excellent chance to provide valuable insights that could guide the development of this Rheumatoid Arthritis asset, while also allowing us to begin expanding our project pipeline for the next financial year."

For more information about Physiomics and its services, please visit www.physiomics.co.uk.

Enquiries:

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

Notes to Editor

About Physiomics

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.